Category Health & IP

Innovation And Access: Fission Or Fusion? Interview With Jennifer Dent, President, BIO Ventures For Global Health (BVGH)

In the light of the UN High-Level Panel on Access to Medicines, this series of sponsored articles challenges experts to give their views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. The views expressed in the articles are those of the authors. Below is an interview with Jennifer Dent, President, BIO Ventures for Global Health (BVGH).

WHO Debates Expansion Of Role In Virus-Sharing

The global treatment of influenza is under reconsideration at the World Health Organization this week, as a review group of a WHO influenza pandemic framework looks at issues such as its relationship with an international treaty protecting countries’ ownership biological resources.

WHO Flu Pandemic Framework Working, Group Says; Some Concerned

A World Health Organization framework to respond to influenza pandemics is working successfully, the confidential draft report of a review team has found. But some areas, such as virus genetic information, still need more work. Stakeholders, meanwhile, are challenging some findings and a concern was raised that lawyers may be influencing the science behind decisions on this issue.

Virus Sharing Key Against Next Flu Pandemic: Global Database Hosts Genetic Data Of Flu Viruses

When a deadly influenza virus appears and threatens to become a pandemic, time is of the essence. The 1918 flu epidemic infected a large portion of the global population and killed millions of people. The next pandemic is inevitable, and surveillance of flu viruses is essential through the timely sharing of flu virus genetic data with the scientific and research communities. A collaborative database has become prominent in recent years.

WHO Pandemic Flu Review Group Meets Next Week

The review of a World Health Organization mechanism for sharing pandemic influenza viruses while ensuring access to vaccines for developing countries is nearing conclusion. Next week, the reviewers will hold their last meeting, including an open session for governments and stakeholders to share views. The review is addressing issues such as the mechanism’s relationship with other international rules, and how to handle the rising use of genetic data instead of biological samples.

WTO, WHO, WIPO Host Discussions On Antimicrobial Resistance In October

Antimicrobial resistance has been described as a major threat to public health, as infections, even minor, might become killers again, if no new antibiotics are discovered. In October, the World Health Organization, World Intellectual Property Organization and World Trade Organization will join forces for a symposium organised to discuss how to foster innovation, and access.

WHO Africa Region Addresses Strategies On Counterfeits, Malaria, Hepatitis

The 47 members of the World Health Organization African region this week adopted or considered a series of measures aimed at fighting substandard and counterfeit medical products, eliminating malaria and viral hepatitis, and setting a global strategy and plan of action on ageing and health that includes a focus on non-communicable diseases. They also adopted a plan for disease outbreaks and health emergencies.

The Downfall Of Invention: A Broken Patent System

The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to patients. In response, pharmaceutical executives are spending more on lobbying and marketing. Yet for all this attention, most of the proposed solutions for reducing prescription drug costs—tougher negotiations, appeals for transparent R&D costs or investigations into insurers—miss one of the primary sources of the problem: the way we award patents, writes Tahir Amin.

Many Hepatitis C Patients Do Not Have Access To Medicines In India, Group Says

Despite being the global leader of generic drug manufacturing, access to hepatitis C treatment in India remains out of reach for a large portion of the population, a civil society group has said in a new paper. The authors call for India to work on a national programme of prevention and treatment of hepatitis, and warn against voluntary licences developed by multinational pharmaceutical companies.